Javascript must be enabled to continue!
Folliculotropic mycosis fungoides: clinical and epidemiological evaluation in a single center in Brazil
View through CrossRef
AbstractBackgroundFolliculotropic mycosis fungoides (FMF) is a rare variant of mycosis fungoides with clinical peculiarities, refractoriness to conventional treatments, and worse prognosis when compared to classic mycosis fungoides.ObjectiveTo evaluate the clinical and epidemiological characteristics of FMF patients in a single center in Brazil.MethodsData were retrospectively collected from patients with FMF who attended the Cutaneous Lymphoma Clinic, University of São Paulo Medical School, between 1987 and 2013.ResultsThirty‐three patients were included (median age 46 years old at diagnosis; 20 male; 27 white). The median disease duration before diagnosis was 3 years. Regarding stage at diagnosis, 61% had advanced stage disease (≥IIb). Follicular papules were reported in 66% and alopecia in 59% of the cases. The most involved regions were limbs, followed by trunk and head. Pruritus was present in 81% of the patients. The median time of patients’ follow‐up was 38 months. At the last follow‐up visit, 67% of the patients were alive with active disease, 27% deceased, and 6% were in complete remission. Four patients had large cell transformation. At the time of diagnosis, 25% of the patients showed eosinophilia.LimitationsRetrospective study with partial unavailable data.ConclusionsThe characteristics of our patients with FMF correlated with aspects previously described in the literature, which were at a more advanced stage at diagnosis and had a less favorable outcome. Pruritus is a very common complaint. Large cell transformation should be monitored as it is implicated in poor prognosis.
Title: Folliculotropic mycosis fungoides: clinical and epidemiological evaluation in a single center in Brazil
Description:
AbstractBackgroundFolliculotropic mycosis fungoides (FMF) is a rare variant of mycosis fungoides with clinical peculiarities, refractoriness to conventional treatments, and worse prognosis when compared to classic mycosis fungoides.
ObjectiveTo evaluate the clinical and epidemiological characteristics of FMF patients in a single center in Brazil.
MethodsData were retrospectively collected from patients with FMF who attended the Cutaneous Lymphoma Clinic, University of São Paulo Medical School, between 1987 and 2013.
ResultsThirty‐three patients were included (median age 46 years old at diagnosis; 20 male; 27 white).
The median disease duration before diagnosis was 3 years.
Regarding stage at diagnosis, 61% had advanced stage disease (≥IIb).
Follicular papules were reported in 66% and alopecia in 59% of the cases.
The most involved regions were limbs, followed by trunk and head.
Pruritus was present in 81% of the patients.
The median time of patients’ follow‐up was 38 months.
At the last follow‐up visit, 67% of the patients were alive with active disease, 27% deceased, and 6% were in complete remission.
Four patients had large cell transformation.
At the time of diagnosis, 25% of the patients showed eosinophilia.
LimitationsRetrospective study with partial unavailable data.
ConclusionsThe characteristics of our patients with FMF correlated with aspects previously described in the literature, which were at a more advanced stage at diagnosis and had a less favorable outcome.
Pruritus is a very common complaint.
Large cell transformation should be monitored as it is implicated in poor prognosis.
Related Results
Thyroid Dysfunction in Mycosis Fungoides: Sonographic and Laboratory Insights
Thyroid Dysfunction in Mycosis Fungoides: Sonographic and Laboratory Insights
Introduction: Thyroid gland affection in mycosis fungoides has been rarely reported. It occurs as extracutaneous involvement, incidentally, as a second malignancy, or as a side eff...
CD4/CD8 double-negative mycosis fungoides: a review
CD4/CD8 double-negative mycosis fungoides: a review
Mycosis Fungoides (MF) stands as the predominant form of primary cutaneous T-cell lymphoma (CTCL). It manifests a diverse array of clinical, histological, and immunophenotypic vari...
Mycosis Fungoides: A differential diagnosis to consider for lichenoid keratosis
Mycosis Fungoides: A differential diagnosis to consider for lichenoid keratosis
Mycosis fungoides (MF) has a wide spectrum of presentation. Its clinic is polymorphic, leading to several clinical variants. Chronic diffuse hyperpigmented lesions can be found in ...
Bleomycin Therapy in Mycosis fungoides
Bleomycin Therapy in Mycosis fungoides
Nine patients with mycosis fungoides in different stages were treated with Bleomycin. Much better results were obtained with this new drug in the six patients with the infiltrative...
Pediatric Hypopigmented Mycosis Fungoides: A Narrative Literature Review of Phototherapy Dosing Regimens
Pediatric Hypopigmented Mycosis Fungoides: A Narrative Literature Review of Phototherapy Dosing Regimens
Background
Mycosis fungoides is the most common type of childhood‐onset primary cutaneous T‐cell lymphoma, and hypopigmented mycosis fungoides (hMF) is a rare, ...
Immunohistochemical expression of IL‐10 in mycosis fungoides
Immunohistochemical expression of IL‐10 in mycosis fungoides
Abstract Immunoreactivity of the cytokine IL‐10 has been investigated in situ in mycosis fungoides (MF). Expression of IL‐10 was detected using immunohistochemistry in skin biopsie...
Two distinct variants of mycosis fungoides (MF): Folliculotropic MF and erythrodermic MF
Two distinct variants of mycosis fungoides (MF): Folliculotropic MF and erythrodermic MF
AbstractMycosis fungoides (MF) is the most frequent type of cutaneous T‐cell lymphoma. Folliculotropic MF (fMF) and erythrodermic MF (eMF) are two distinct variants of MF. Both var...
Prognostic Value of Immunohistochemical T-Cell Marker Loss in Early-Stage Mycosis Fungoides: A Single-Center Cohort Study
Prognostic Value of Immunohistochemical T-Cell Marker Loss in Early-Stage Mycosis Fungoides: A Single-Center Cohort Study
Introduction: Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma, often exhibiting loss of pan-T-cell markers such as CD2, CD3, CD5, and CD7. While these immunophe...

